Literature DB >> 8815576

The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.

J Nishioka1, M Ido, T Hayashi, K Suzuki.   

Abstract

A functionally defective protein C (PC)-Mie, detected the plasma of a patient with hereditary thrombophilia, has Lys substituted for gamma-carboxyglutamic acid (Gla)26 residue. The activation rate of PC-Mie by Protac or thrombin in the absence of Ca2+ and that by thrombin with native thrombomodulin (TM), recombinant soluble truncated TM or on cultured endothelial cells in the presence of Ca2+ were all apparently lower than that of normal PC. The anticoagulant activity of Protac-activated PC (APC)-Mie on the plasma clotting time and the rate of inactivation of factor Va by APC-Mie in the presence of phospholipids were lower than those seen with normal APC. APC-Mie and normal APC bound equally to protein S and to biotinyl-factor Va. However, neither PC-Mie nor APC-Mie bound to phospholipids and to cultured human endothelial cells. It was similar to that observed with Gladomainless PC/APC, but different from that seen with normal PC/APC. These results suggest that Gla26-dependent conformation is required for the binding of PC/APC to phospholipids, TM and the surface of endothelial cell PC/APC receptor, but not to protein S and factor Va.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815576

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  Modeling zymogen protein C.

Authors:  L Perera; C Foley; T A Darden; D Stafford; T Mather; C T Esmon; L G Pedersen
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

2.  Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor.

Authors:  K Fukudome; X Ye; N Tsuneyoshi; O Tokunaga; K Sugawara; H Mizokami; M Kimoto
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.